Lancet Regional Health-Europe最新文献

{"title":"Intranasal versus intravenous administration of analgesia — authors’ reply","authors":"Michael A. Smyth , Joyce Yeung , Gavin D. Perkins","doi":"10.1016/j.lanepe.2025.101462","DOIUrl":"10.1016/j.lanepe.2025.101462","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101462"},"PeriodicalIF":13.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soldiers, not by choice: confronting conscription as a public health harm","authors":"Samuel Christopher Rogers , Ralph Hurley O'Dwyer","doi":"10.1016/j.lanepe.2025.101461","DOIUrl":"10.1016/j.lanepe.2025.101461","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101461"},"PeriodicalIF":13.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental well-being in adolescence and eight years of follow-up for mental illness, risky behaviours, and mortality in 67,945 15–19-year-olds: a prospective cohort study","authors":"Janne S. Tolstrup , Sara Rudbæk Larsen , Ian Kelleher , Mary Cannon , Christina Viskum Lytken Larsen , Merete Nordentoft","doi":"10.1016/j.lanepe.2025.101435","DOIUrl":"10.1016/j.lanepe.2025.101435","url":null,"abstract":"<div><h3>Background</h3><div>Adolescence is a sensitive developmental period during which complaints of poor mental well-being increase drastically. We investigated how social determinants associated with self-reported mental well-being and how self-reported mental well-being associated prospectively from adolescence to young adulthood with mental illness, risky behaviours, and mortality.</div></div><div><h3>Methods</h3><div>We used data on 67,945 Danish students aged 15–19, surveyed in 2014 (baseline). We employed a person-centred approach using Latent Class Analysis to define mental well-being subgroups with nine indicators of mental well-being: life satisfaction, self-esteem, irritability, low mood, stress, loneliness, self-efficacy, and confidence in parents and friends. By linkage to national health, social, and mortality registers, we obtained information on social determinants at baseline and the following outcomes during young adulthood: Mental illness, self-harm and suicide attempts, alcohol-related and substance use-related hospital contacts, emergency room contacts due to interpersonal violence, and all-cause mortality. Descriptive statistics were produced to illustrate associations between social determinants and mental well-being, and Poisson and Cox regression were used to estimate incidence rates and hazard ratios over the 8.2-year follow-up period.</div></div><div><h3>Findings</h3><div>We identified four distinct groups of mental well-being: Good (32%), Moderate (35%), Poor (19%), and Very Poor (14%). We observed pronounced gradients of social and familial disadvantage such as financial difficulties and parental alcohol problems across mental well-being groups, with greater disadvantage linked to poorer mental well-being. The risk of mental illness, self-harm and suicide attempts, alcohol-related and substance use-related hospital contacts, emergency room contacts due to interpersonal violence, and all-cause mortality was consistently lowest in the Good, at intermediate levels in the Moderate and Poor, and substantially higher in those with Very Poor mental well-being. For example, hazard ratios for mental illness were 1.51 (95% CI = 1.39, 1.64), 2.61 (2.41, 2.82) and 5.32 (4.92, 5.76) in the Moderate, Poor and Very Poor, respectively, corresponding to incidence rate differences of 27.2 (21.5, 32.8), 85.5 (77.4, 93.5) and 230 (214, 246) per 10,000, as compared to the Good mental well-being group. The higher risk of all outcomes remained across 8.2 years of follow-up. The external validity of findings was confirmed by repeating all analyses in independent data.</div></div><div><h3>Interpretation</h3><div>Our study reveals that poor adolescent mental well-being, as operationalised multidimensionally from self-reported information, predicts adverse outcomes and even mortality during young adulthood. These findings urgently call for mental health complaints in adolescents to be taken seriously and prioritised for identification and in","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"58 ","pages":"Article 101435"},"PeriodicalIF":13.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies","authors":"Hugo Jourdain ,&nbsp;Antonio Di Meglio ,&nbsp;Imène Mansouri ,&nbsp;David Desplas ,&nbsp;Mahmoud Zureik ,&nbsp;Nadia Haddy","doi":"10.1016/j.lanepe.2025.101455","DOIUrl":"10.1016/j.lanepe.2025.101455","url":null,"abstract":"<div><h3>Background</h3><div>The management of HER2-positive metastatic breast cancer (HER2⁺ mBC) has rapidly evolved. We assessed the real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) and tucatinib by emulating two phase III trials.</div></div><div><h3>Methods</h3><div>We emulated two target trials using the French National Health Data System: T-DXd versus T-DM1 and T-DXd versus tucatinib, for second- and third-line HER2⁺ mBC treatment. We included patients from September 2020 to September 2023, and followed them until death or April 2024. We emulated treatment assignment randomization with inverse probability of treatment weighting. Efficacy outcomes included time to treatment discontinuation (TTD) and overall survival (OS). Safety outcomes included cause-specific hospitalizations.</div></div><div><h3>Findings</h3><div>In the second-line treatment emulation (<em>n</em> = 2931: 1633 T-DM1, 1298 T-DXd), T-DXd had longer TTD (median 14⋅1 versus 6⋅5 months; weighted hazard ratio, wHR [95% confidence interval, CI], 0⋅46 [0⋅42–0⋅51]) and OS (median not reached; wHR [95% CI], 0⋅66 [0⋅55–0⋅80]) than T-DM1. We observed more cases of interstitial lung disease in the T-DXd group. In the third-line treatment emulation (<em>n</em> = 2391: 566 tucatinib, 1825 T-DXd), T-DXd had longer TTD (median 11⋅8 versus 5⋅8 months; wHR [95% CI], 0⋅60 [0⋅53–0⋅68]) and OS (median 31⋅7 versus 26⋅6 months; wHR [95% CI], 0⋅79 [0⋅69–0⋅92]) than tucatinib. T-DXd tended to protect from cardiac disorders (wHR [95% CI], 0⋅44 [0⋅26–0⋅74]) while enhancing respiratory disorders occurrence (wHR [95% CI], 1⋅72 [1⋅03–2⋅89]).</div></div><div><h3>Interpretation</h3><div>In this real-world study, T-DXd was more effective than T-DM1 as a second-line treatment and tucatinib as a third-line treatment, in line with clinical trial results.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"58 ","pages":"Article 101455"},"PeriodicalIF":13.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and functioning outcomes during the establishment phase of Ukraine's community mental health teams: a descriptive analysis","authors":"Alisa Ladyk-Bryzghalova ,&nbsp;Charles Zemp ,&nbsp;Marjolaine Rivest-Beauregard ,&nbsp;Oleksii Kostiuchenkov ,&nbsp;Alison Schafer ,&nbsp;Ben Adams ,&nbsp;Dan Chisholm ,&nbsp;Philip Hyland ,&nbsp;Mel Ó Súird ,&nbsp;Katerina Drakos ,&nbsp;Iryna Mykychak ,&nbsp;Jarno Habicht ,&nbsp;Frédérique Vallières","doi":"10.1016/j.lanepe.2025.101446","DOIUrl":"10.1016/j.lanepe.2025.101446","url":null,"abstract":"<div><h3>Background</h3><div>Ukraine's nationwide Community Mental Health Teams (CMHTs) programme is key to Ukraine's ongoing mental healthcare reform. No studies to date, however, have reported on the impact of Ukrainian CMHTs on service user clinical recovery. This study has two aims: (i) describe <em>who</em> the Ukrainian CMHTs are enrolling, <em>which</em> services they most provide, and <em>where</em> they are provided and (ii) identify whether any clinical and/or functional improvements were detectable among service users after six CMHT visits (intake + five follow-up visits) and, if so, identify principal predictors of such improvements.</div></div><div><h3>Methods</h3><div>947 CMHT service users enrolled between April–December 2021 were assessed on clinical outcomes using the Clinical Global Improvement scale (CGI) and functional outcomes using WHO's Disability Assessment Schedule (WHODAS 2·0). Chi-square and Wilcoxon signed-rank tests were used to assess changes in CGI and WHODAS scores, respectively, at the fifth (or fourth) follow-up CMHT visit. Hierarchical multinomial logistic regression and hierarchical multiple linear regression identified predictors of clinical and functional improvement, respectively.</div></div><div><h3>Findings</h3><div>Most service users were male, unemployed, and diagnosed with schizophrenia spectrum disorders. Among service users with available outcome data at both CMHT intake and the fifth (or fourth) follow-up visit, a significant decrease in disability scores was observed (Median_intake = 62·50, Median_follow-up = 58·33, <em>z</em> = −6·27, <em>p</em> &lt; 0·001) and most service users' illness severity stabilised (n = 451/742, 60·8%) or improved (n = 243/742, 32·6%). Clinical stabilisation (compared to worsening) was predicted by being male and living &lt;20 km from the CMHT office, while improvement was predicted by frequent receipt of pharmacological support and receiving CMHT care in non-conflict-exposed regions. Functional improvement was predicted by living between 20 and 100 km from the CMHT office, having a somatic comorbidity, more frequent receipt of psychosocial services for the service user's family, and more support for community integration.</div></div><div><h3>Interpretation</h3><div>We found positive results associated with enrolment in Ukraine's CMHTs. Recommendations for future research and improvements to the CMHT programming are provided.</div></div><div><h3>Funding</h3><div>Funded as part of the <span>World Health Organization's Special Initiative for Mental Health</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"58 ","pages":"Article 101446"},"PeriodicalIF":13.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study","authors":"Maria Angeliki Toli ,&nbsp;Xingrong Liu ,&nbsp;Davide Massa ,&nbsp;Stefania Lando ,&nbsp;Caroline Boman ,&nbsp;Nikolaos Tsiknakis ,&nbsp;Christian Tranchell ,&nbsp;Andri Papakonstantinou ,&nbsp;Giuseppe Fotia ,&nbsp;Claudio Vernieri ,&nbsp;Valentina Guarneri ,&nbsp;Jonas Bergh ,&nbsp;Maria Vittoria Dieci ,&nbsp;Louise Eriksson Bergman ,&nbsp;Alexios Matikas ,&nbsp;Theodoros Foukakis","doi":"10.1016/j.lanepe.2025.101432","DOIUrl":"10.1016/j.lanepe.2025.101432","url":null,"abstract":"<div><h3>Background</h3><div>Although Ki-67 is a commonly used proliferation marker in breast cancer (BC), its prognostic value after neoadjuvant chemotherapy (NACT) remains unclear. This study aims to investigate the prognostic implications of Ki-67 dynamics during NACT.</div></div><div><h3>Methods</h3><div>Patients with invasive BC treated with NACT (2007–2020) were identified through the National Breast Cancer Register (NBCR). Associations between Ki-67 dynamics with survival outcomes were studied (spline-based Cox regression). The prognostic value of Ki-67 in the Neo-Bioscore model was examined and optimal cut-off values for relative change of Ki-67 ((post-NACT–pre-NACT Ki-67)/pre-NACT Ki-67) were explored (minimum p-value approach).</div></div><div><h3>Findings</h3><div>Among 2494 patients, median pre-NACT Ki-67 was 40% (IQR:28–65%). Median post-NACT Ki-67 in patients with residual disease (n = 1826) was 12% (IQR:5–35%). Lower post-NACT Ki-67 was associated with better breast cancer specific survival (BCSS) in the whole cohort (p &lt; 0.0001), in ER+/HER2− (p = 0.0001) and TNBC (p = 0.0007), but not in HER2+ BC (p = 0.8223). Post-NACT Ki-67 improved the Neo-Bioscore prognostic model increasing the C-index from 0.758 to 0.802. Post-NACT Ki-67, as well as absolute and relative change of Ki-67 were strongly correlated with each other and were prognostic for long-term outcomes. Optimal cut-off values for relative change of Ki-67 identified prognostic subgroups for ER+/HER2− BC (n = 730, p &lt; 0.0001), and TNBC (n = 279, p &lt; 0.0001). The results were validated in an external TNBC cohort of 221 patients (p = 0.00073). Notably, the identified low-risk patients with residual disease and at least 48% reduction of Ki-67 after NACT, had comparable survival to those with pathological complete response (pCR) (p = 0.13).</div></div><div><h3>Interpretation</h3><div>Relative change of Ki-67 was independently prognostic for patient risk stratification. Ki-67 in residual disease warrants for further investigation when exploring post-neoadjuvant treatment strategies.</div></div><div><h3>Funding</h3><div><span>Cancerfonden</span>, <span>Vetenskapsrådet</span>, <span>Cancerföreningen i Stockholm</span> and <span>Region Stockholm</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"58 ","pages":"Article 101432"},"PeriodicalIF":13.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study","authors":"Devin M. Razavi-Shearer ,&nbsp;Loreta A. Kondili ,&nbsp;Samantha Hall ,&nbsp;Maria Buti ,&nbsp;Ivane Gamkrelidze ,&nbsp;Marcelo C.M. Naveira ,&nbsp;Helen Nde ,&nbsp;Francesco Negro ,&nbsp;Andrea Osmani ,&nbsp;Camila A. Picchio ,&nbsp;Kathryn Razavi-Shearer ,&nbsp;Alexis S. Voeller ,&nbsp;Homie A. Razavi","doi":"10.1016/j.lanepe.2025.101452","DOIUrl":"10.1016/j.lanepe.2025.101452","url":null,"abstract":"<div><h3>Background</h3><div>In countries with low baseline burdens of hepatitis B and C viruses (HBV, HCV), high levels of migration can impact the burden of viral hepatitis. The screening and treatment of migrants requires different methods and sensitivities than broad-based programs. We aimed to estimate the prevalence of HBV and HCV among migrants in EU-27 countries in 2024. The Ukrainian Refugee Crisis was also quantified.</div></div><div><h3>Methods</h3><div>Using the United Nations 2024 migrant stock data, we estimated the migrant population for each EU-27 country by five-year age and sex cohorts by country of birth. These distributions were multiplied by five-year age and sex prevalence estimates in the country-of-birth models maintained by the Polaris Observatory. The difference between the 2024 and 2020 Ukrainian migrant stock was quantified to estimate the impact of the Ukrainian Refugee Crisis.</div></div><div><h3>Findings</h3><div>In 2024, there were an estimated 1.73 million (UI: 1.04–2.66 million) migrants living with HBV and 1.03 million (UI: 757,000–1,559,000) living with anti-HCV in the EU-27, corresponding to migrant prevalences of 2.73% (UI: 1.6–4.2%) and 1.53% (UI: 1.2–2.5%) respectively. The Ukrainian Refugee Crisis is estimated to have resulted in an additional 43,000 (UI: 28,700–60,900) migrants living with HBV, and 154,000 (UI: 12,500–202,000) with HCV in the EU-27.</div></div><div><h3>Interpretation</h3><div>The burden of HBV and HCV among migrants and which communities are most affected in the EU-27 at the national level are vastly heterogeneous. These data provide evidence for policy makers to better understand the burden their community faces so that they can be better poised to develop culturally appropriate materials and outreach. While there is a great deal of uncertainty regarding the number of migrants by country, as well as the prevalence among these groups, this work provides direction towards which groups are most likely impacted at the EU-27 and national level.</div></div><div><h3>Funding</h3><div><span>John C Martin Foundation</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"58 ","pages":"Article 101452"},"PeriodicalIF":13.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144926354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in hospital-recorded pulmonary embolism in England before, during and after the COVID-19 pandemic (2008–2024): a population-based observational study","authors":"Xiaomin Zhong ,&nbsp;James Webster ,&nbsp;Eva J.A. Morris ,&nbsp;Emre Oguzman ,&nbsp;Susan Shapiro ,&nbsp;Sasha Shepperd ,&nbsp;Raph Goldacre","doi":"10.1016/j.lanepe.2025.101433","DOIUrl":"10.1016/j.lanepe.2025.101433","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 infection increases the risk of pulmonary embolism (PE). Up-to-date reporting of hospitalisation rates for PE is needed to inform service planning and for benchmarking in light of the pandemic. Our primary aim was to quantify monthly trends in first-time, hospital-recorded PE across England from 2008 to 2024, with particular focus on the pandemic period. A secondary aim was to examine how these trends varied by age, sex, socioeconomic deprivation, and region, providing ongoing public access through an interactive online dashboard.</div></div><div><h3>Methods</h3><div>We conducted an epidemiological population-based study of all first-time PE diagnoses using English national secondary care data from April 2008 to December 2024. Trends before and after the onset of the COVID-19 pandemic (March 2020) were compared, with analyses by age, sex, region, and deprivation.</div></div><div><h3>Findings</h3><div>A total of 750,109 first-time PE admissions were identified. Age-standardised first-time hospital-recorded PE rates rose from 5.4 per 100,000 population in April 2008 to 8.5 in January 2020, spiked to 16.8 in January 2021 during the pandemic. The spike was largely accounted for by PEs where COVID-19 was a co-existing diagnosis. Rates have since declined, returning to pre-pandemic levels by early 2023 (e.g. March 2023, 8.6 per 100,000), and may be continuing to decline, subject to further updates. Regional and deprivation gradients persisted throughout but were more pronounced during the pandemic.</div></div><div><h3>Interpretation</h3><div>Whilst incidence of hospital-recorded PE spiked during the COVID-19 pandemic, rates have since returned to levels observed immediately prior to the pre-pandemic. Whilst it is too early to determine whether the recent downward trend may begin to reverse some of the upward trend observed over the decade before the pandemic, continued surveillance of hospital-recorded PE reported via our online tool will keep these findings up to date. Ongoing monitoring of PE incidence by healthcare setting is important to undertake while clinical practice and policy on PE management pathways evolve, since it helps to support care planning; it also informs data-enabled clinical trials where PE is an outcome as well as the design of observational studies.</div></div><div><h3>Funding</h3><div>This work was supported by the <span>NIHR Biomedical Research Centre</span>, Oxford and by <span>Health Data Research UK</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"58 ","pages":"Article 101433"},"PeriodicalIF":13.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144926353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"West Nile in Italy: a new health challenge or human failure?","authors":"Francesco Branda ,&nbsp;Giancarlo Ceccarelli ,&nbsp;Marta Giovanetti ,&nbsp;Fabio Scarpa ,&nbsp;Massimo Ciccozzi","doi":"10.1016/j.lanepe.2025.101440","DOIUrl":"10.1016/j.lanepe.2025.101440","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"57 ","pages":"Article 101440"},"PeriodicalIF":13.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italy’s NITAG shift: implications for public trust in vaccines","authors":"Virginia Casigliani,&nbsp;Francesco Gesualdo,&nbsp;Lara Tavoschi,&nbsp;Caterina Rizzo","doi":"10.1016/j.lanepe.2025.101449","DOIUrl":"10.1016/j.lanepe.2025.101449","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"58 ","pages":"Article 101449"},"PeriodicalIF":13.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}